Paper19252746
COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
Wagemakers M and 9 others. Transl Oncol, 2009. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature. Papers, record 19252746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19252746
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15972838 | Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. | Am J Physiol Cell Physiol | 2005 | https://conductscience.org/library/papers/15972838 | PubMed |
| 2 | 10987308 | Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. | Cancer Res | 2000 | https://conductscience.org/library/papers/10987308 | PubMed |
| 3 | 15637262 | Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. | Science | 2005 | https://conductscience.org/library/papers/15637262 | PubMed |
| 4 | 2369725 | Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. | Cancer Res | 1990 | https://conductscience.org/library/papers/2369725 | PubMed |
| 5 | 10728691 | Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. | Cancer Res | 2000 | https://conductscience.org/library/papers/10728691 | PubMed |
| 6 | 11754039 | Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. | Biopharm Drug Dispos | 2001 | https://conductscience.org/library/papers/11754039 | PubMed |
| 7 | 11606477 | COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. | FASEB J | 2001 | https://conductscience.org/library/papers/11606477 | PubMed |
| 8 | 15179620 | Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. | Semin Oncol | 2004 | https://conductscience.org/library/papers/15179620 | PubMed |
| 9 | 14751505 | Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. | Int J Radiat Oncol Biol Phys | 2004 | https://conductscience.org/library/papers/14751505 | PubMed |
| 10 | 14519750 | Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? | J Natl Cancer Inst | 2003 | https://conductscience.org/library/papers/14519750 | PubMed |
| 11 | 11830509 | Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. | Cancer Res | 2002 | https://conductscience.org/library/papers/11830509 | PubMed |
| 12 | 15175435 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15175435 | PubMed |
| 13 | 8551390 | Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. | J Pathol | 1995 | https://conductscience.org/library/papers/8551390 | PubMed |
| 14 | 15607960 | Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Cancer Cell | 2004 | https://conductscience.org/library/papers/15607960 | PubMed |
| 15 | 12142044 | Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. | Eur J Cancer | 2002 | https://conductscience.org/library/papers/12142044 | PubMed |
| 16 | 10469752 | Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. | J Natl Cancer Inst | 1999 | https://conductscience.org/library/papers/10469752 | PubMed |
| 17 | 15015658 | Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089. | J Neurooncol | 2004 | https://conductscience.org/library/papers/15015658 | PubMed |
| 18 | 10728694 | Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. | Cancer Res | 2000 | https://conductscience.org/library/papers/10728694 | PubMed |
| 19 | 11389063 | Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. | Cancer Res | 2001 | https://conductscience.org/library/papers/11389063 | PubMed |
| 20 | 10873107 | Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10873107 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41607422 | The combination of rosuvastatin and meloxicam enhances the radiotherapy efficacy of MCF7, T-47D, and MDA-MB-231 breast cancer cell lines. | Res Pharm Sci | 2026 | https://conductscience.org/library/papers/41607422 | PubMed |
| 39339469 | Some Aspects and Convergence of Human and Veterinary Drug Repositioning. | Molecules | 2024 | https://conductscience.org/library/papers/39339469 | PubMed |
| 38585299 | A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs. | Front Vet Sci | 2024 | https://conductscience.org/library/papers/38585299 | PubMed |
| 35734224 | Effect of Parecoxib Sodium Preemptive Analgesia on the Recovery Period of General Anesthesia in Patients Undergoing Glioma Resection. | J Oncol | 2022 | https://conductscience.org/library/papers/35734224 | PubMed |
| 35042267 | Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays. | Drug Res (Stuttg) | 2022 | https://conductscience.org/library/papers/35042267 | PubMed |
| 35038171 | Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood. | J Vet Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35038171 | PubMed |
| 34886785 | Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways. | Drug Metab Lett | 2021 | https://conductscience.org/library/papers/34886785 | PubMed |
| 34854245 | Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic-guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model. | Vet Med Sci | 2022 | https://conductscience.org/library/papers/34854245 | PubMed |
| 34160092 | Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration. | J Vet Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34160092 | PubMed |
| 34082759 | Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months. | BMC Vet Res | 2021 | https://conductscience.org/library/papers/34082759 | PubMed |
| 33806933 | Contemporary Mouse Models in Glioma Research. | Cells | 2021 | https://conductscience.org/library/papers/33806933 | PubMed |
| 30715649 | Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro. | Mol Neurobiol | 2019 | https://conductscience.org/library/papers/30715649 | PubMed |
| 30584371 | Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. | Cancer Manag Res | 2018 | https://conductscience.org/library/papers/30584371 | PubMed |
| 29254264 | Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis. | Oncotarget | 2017 | https://conductscience.org/library/papers/29254264 | PubMed |
| 27104573 | Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review. | Antioxidants (Basel) | 2016 | https://conductscience.org/library/papers/27104573 | PubMed |
| 26871579 | Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma. | PLoS One | 2016 | https://conductscience.org/library/papers/26871579 | PubMed |
| 24416158 | Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation. | PLoS One | 2014 | https://conductscience.org/library/papers/24416158 | PubMed |
| 24281089 | Role of inflammation and oxidative stress mediators in gliomas. | Cancers (Basel) | 2010 | https://conductscience.org/library/papers/24281089 | PubMed |
| 23280445 | Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. | J Neurosci Res | 2013 | https://conductscience.org/library/papers/23280445 | PubMed |
| 22678114 | Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. | Carcinogenesis | 2012 | https://conductscience.org/library/papers/22678114 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19252746
GET https://conductscience.org/api/papers/v1/19252746/references?page=2